Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
CagriSema is an experimental, once-weekly injection currently under investigation as a weight-loss treatment for adults with obesity or overweight, including some who have type 2 diabetes. The medication pairs cagrilintide, which mimics the natural hunger-regulating hormone amylin, with semaglutide, a GLP-1 agonist. These ingredients may help increase feelings of fullness, slow how fast the stomach empties, and support blood sugar control. CagriSema has not yet been cleared by the FDA, Health Canada, or other regulatory agencies, so the details below could change once an official approval and label become available.
| Fact Table | |
|---|---|
| Formula | Cagrilintide: C273H420N74O81S1; Semaglutide: C187H291N45O59 |
| License | Investigational (Phase 3) |
| Bioavailability | Subcutaneous: Moderate (semaglutide ~89%) |
| Legal status | Not yet approved |
| Chemical Name | Cagrilintide and Semaglutide (synthetic peptides) |
| Elimination half-life | Cagrilintide: ~8 days; Semaglutide: ~7 days |
| Dosage (Strength) | Investigational doses (e.g., Cagrilintide 2.4 mg + Semaglutide 2.4 mg weekly) |
| Pregnancy | Not established; consult healthcare provider |
| Brands | CagriSema (developmental) |
| Protein binding | Semaglutide: >99%; Cagrilintide: Not well documented |
| PubChem CID | Semaglutide: 56843331; Cagrilintide: Not listed |
| MedlinePlus | Not assigned |
| ChEBI | Semaglutide: 145346; Cagrilintide: Not available |
| ATC code | Not yet assigned |
| DrugBank | Semaglutide: DB13928; Cagrilintide: Not listed |
| KEGG | Semaglutide: D10590; Cagrilintide: Not listed |
| Routes of administration | Subcutaneous injection (once weekly) |
CagriSema remains under study and has no approved dosing plan. It should be used only as part of an approved clinical trial or as a healthcare provider directs. In phase 3 research, the drug was given as a weekly injection beneath the skin, typically in the abdomen, thigh, or upper arm. Dosing starts low and is gradually increased over several weeks to let the body adjust and limit side effects such as nausea.
A missed dose may be taken as soon as possible within a set window of days. Otherwise, it should be skipped. Never use two doses together to make up for one that was missed. CagriSema is intended to be used alongside a reduced-calorie diet and increased physical activity.
The active ingredients are cagrilintide and semaglutide.
Before starting this medication, it may help to discuss the following with a healthcare provider:
CagriSema is an investigational drug that should be taken only with medical oversight, as its long-term safety has not yet been fully established.
In animal studies, semaglutide was associated with thyroid tumors, including medullary thyroid carcinoma. Whether this occurs in humans is not known. Let your provider know if you notice a lump or swelling in the neck, hoarseness, or trouble swallowing.
Digestive side effects like nausea, vomiting, and diarrhea can occur, especially when first starting or increasing the dose. Severe or ongoing vomiting or diarrhea may cause dehydration that can affect the kidneys.
GLP-1 receptor agonists such as semaglutide have been connected to pancreatitis, or inflammation of the pancreas, and gallbladder issues. Get medical care for intense, persistent stomach pain that may spread to the back, fever, or yellowing of the skin or eyes.
For people with type 2 diabetes who also take insulin or medicines that raise insulin levels, such as sulfonylureas, the chance of low blood sugar, also called hypoglycemia, may increase, and the doses of those medicines might need to be reduced.
If you have a history of diabetic eye disease, also called diabetic retinopathy, your healthcare provider may keep an eye on your vision, since quick shifts in blood sugar can influence this condition.
Because CagriSema slows stomach emptying, it can change how food and other oral medicines are absorbed. Let your healthcare team, including any surgeon or anesthesiologist, know you use it ahead of a scheduled surgery or procedure.
Since semaglutide stays in the body for an extended time, it should be discontinued well in advance of a planned pregnancy.
CagriSema does not yet have an approved label listing contraindications. Based on its ingredients and the enrollment criteria from clinical studies, it should not be used if any of the following apply:
The side effects most often reported with CagriSema in clinical trials were gastrointestinal. They were generally mild to moderate, usually appeared when treatment started or the dose increased, and were temporary. They include:
More serious reactions are possible. Get medical help for signs of a serious allergic reaction, such as difficulty breathing, a severe rash, or swelling of the face, lips, tongue, or throat. Report any severe or lasting stomach pain that may move toward the back, symptoms of gallbladder trouble, or signs of low blood sugar such as shaking, sweating, confusion, or a rapid heartbeat. Also, seek medical advice for severe vomiting and diarrhea, as well as any new neck lump or swelling, hoarseness, or difficulty swallowing.
What is CagriSema?
CagriSema is a combination medication containing cagrilintide and semaglutide, designed for weight management and metabolic health improvement.
How does CagriSema work?
CagriSema works through dual mechanisms: semaglutide mimics GLP-1 to regulate appetite and slow gastric emptying, while cagrilintide acts as an amylin analog to enhance satiety and complement the effects of semaglutide.
How is CagriSema administered?
CagriSema is administered as a once-weekly subcutaneous injection using a pre-filled pen device.
What kind of weight loss results can I expect with CagriSema?
Clinical trials have shown that patients using CagriSema may experience significant weight loss, potentially greater than with either medication alone, with many patients losing 15-20% of their initial body weight.
What are the most common side effects of CagriSema?
Common side effects include nausea, vomiting, diarrhea, constipation, and injection site reactions. These typically decrease in intensity over time as your body adjusts to the medication.
Is CagriSema suitable for patients with diabetes?
CagriSema may be suitable for patients with type 2 diabetes, as both components can help improve glycemic control. However, dosing may need to be adjusted, and close monitoring by a healthcare provider is essential.
How long does it take to see results with CagriSema?
Most patients begin to notice weight loss within the first 4-8 weeks of treatment, with maximum effects typically observed after 6-12 months of consistent use.
Can I stop taking CagriSema once I reach my target weight?
CagriSema is generally considered a long-term treatment. Discontinuing the medication often results in weight regain, so any decision to stop should be discussed with your healthcare provider.
Do I need to follow a specific diet while taking CagriSema?
While CagriSema can help reduce appetite, it works best when combined with a healthy, balanced diet and regular physical activity as recommended by your healthcare provider.
Can CagriSema interact with other medications?
CagriSema may interact with certain medications, particularly those that affect blood sugar or are absorbed in the gastrointestinal tract. Always inform your healthcare provider about all medications you're taking.
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews